Effect of Oxygen Therapy for Patients With Precapillary Pulmonary Hypertension Who Experience an Altitude Related Adverse Health Effect (ARAHE) During 30h Exposure to 2500m

Oxygen Therapy Clinical Trial

Official title:

The Impact of Hypoxia on Patients With Precapillary Pulmonary Hypertension and Treatment of Adverse Effects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05112172
• Other study ID #: OVERALP II B
• Status: Completed
• Phase: N/A
• Start date: October 18, 2021
• Est. completion date: April 15, 2022

Study information

• Verified date: May 2022
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To study whether oxygen therapy titrated to maintain oxygenation (SpO2) > 90% at 2500m would resolve altitude-related adverse health effects, symptoms and impaired exercise during 30h exposure to high altitude.

Description:

Patients with pulmonary hypertension who reveal an altitude-related adverse health effects at 2500m will be given oxygen therapy by nasal cannula titrated to maintain the oxygen saturation above 90%. The study will investigate, whether this measure will restore altitude-induced impairment to baseline levels at low altitude.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: April 15, 2022
• Est. primary completion date: April 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Informed consent as documented by signature

• PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure >20 mmHg, pulmonary vascular resistance =3 wood units, pulmonary arterial wedge pressure =15 mmHg during baseline measures at the diagnostic right-heart catheterization

Exclusion Criteria:

• resting partial pressure of oxygen <8 kilopascal at Zurich at 490 m low altitude

• exposure to an altitude >1000 m for =3 nights during the last 2 weeks before the study

• inability to follow the procedures of the study

• other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)

Related Conditions & MeSH terms

• High Altitude Pulmonary Hypertension
• Hypertension
• Hypertension, Pulmonary
• Oxygen Therapy

Intervention

Other:
• Oxygen Therapy
Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude

Locations

Country	Name	City	State
Switzerland	Respiratory Clinic, University Hospital of Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recovery from ARAHE	Proportion of patients with precapillary pulmonary hypertension experiencing an ARAHE at 2500 m of high altitude and receiving oxygen therapy titrated to achieve SpO2 = 90% who recover from ARAHE, have improved symptoms and achieve constant work-rate exercise time within a minimal important difference as defined for patients with respiratory disease within 1.75 min of baseline value at 490 m; time frame within 6 h after initiation of oxygen therapy.	30 hours
Secondary	Constant work-rate exercise time	Difference with oxygen therapy at high altitude vs. low altitude in constant work-rate exercise time cycle exercise test at 75% Wmax at low altitude	30 hours
Secondary	Maximum work-rate in incremental ramp cycle exercise tests	Difference with oxygen therapy at high altitude vs. low altitude in maximal exercise capacity during a incremental ramp cycle exercise test	30 hours
Secondary	Hemodynamics	Difference with oxygen therapy at high altitude vs. low altitude in hemodynamics assessed by echocardiography at rest including pulmonary artery pressure, cardiac output, pulmonary vascular resistance and right heart function assessed as tricuspid plane systolic excursion and fractional area change.	30 hours
Secondary	Borg dyspnoea scale	Difference with oxygen therapy at high altitude vs. low altitude baseline in post-exercise Borg dyspnoea scale going from 1-10 scores with higher values meaning worse dyspnea	30 hours
Secondary	Visual Analogue Scale	Difference with oxygen therapy at high altitude vs. low altitude baseline in symptoms assessed by the Visual Analogue Scale for dyspnoea, a 10cm line from left to right where patients have to add a cross-line with higher values meaning better feeling.	30 hours
Secondary	Cognitive testing	Difference with oxygen therapy at high altitude vs. low altitude baseline in cognitive function tests	30 hours
Secondary	sit-to-stand test	Difference with oxygen therapy at high altitude vs. low altitude baseline in sit-to-stand test	30 hours
Secondary	Sleep disordered breathing	Difference with oxygen therapy at high altitude vs. low altitude in sleep disordered breathing	30 hours
Secondary	6 minute walk test	Difference with oxygen therapy at high altitude vs. low altitude in 6 minute walk test	30 hours
Secondary	Acute Mountain Sickness Score	Difference with oxygen therapy at high altitude vs. low altitude baseline in symptoms assessed by the Lake Louise acute mountain sickness score going from 0-12 points with mild AMS as 3-5 points, moderate AMS as 6-9 points, and severe AMS as 10-12 points.	30 hours